Edition:
United States

Otonomy Inc (OTIC.OQ)

OTIC.OQ on NASDAQ Stock Exchange Global Select Market

12.75USD
4:00pm EDT
Change (% chg)

$0.05 (+0.39%)
Prev Close
$12.70
Open
$12.50
Day's High
$12.90
Day's Low
$12.25
Volume
50,729
Avg. Vol
52,074
52-wk High
$19.36
52-wk Low
$10.53

OTIC.OQ

Chart for OTIC.OQ

About

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time... (more)

Overall

Beta: --
Market Cap(Mil.): $384.26
Shares Outstanding(Mil.): 30.26
Dividend: --
Yield (%): --

Financials

  OTIC.OQ Industry Sector
P/E (TTM): -- 47.76 29.98
EPS (TTM): -3.69 -- --
ROI: -58.96 -2.36 13.08
ROE: -59.09 5.29 14.23

BRIEF-Otonomy loss per share $0.88

* Otonomy reports fourth quarter and full year 2016 financial results and provides corporate update

Mar 02 2017

BRIEF-Otonomy qtrly loss per share $0.88

* Says topline data for oto-104 phase 3 trials expected in 2H2017

Mar 02 2017

BRIEF-Otonomy sees 2017 non-GAAP operating expenses between $85-$90 mln

* Expects non-GAAP operating expenses for 2017 in range of $85-$90 million Source text for Eikon: Further company coverage:

Jan 09 2017

Otonomy's ear infection drug succeeds in late-stage trial

Drug developer Otonomy Inc said on Thursday its drug to treat acute otitis externa (AOE), an infection in the outer ear canal, met the main goal in a late-stage trial.

Jan 05 2017

BRIEF-Otonomy reports third quarter 2016 financial results

* Company reaffirms its expectations that non-GAAP operating expenses for 2016 will total $100-$105 million

Nov 03 2016

BRIEF-Otonomy to report Q3 2016 financial results and provide corporate update

* Otonomy to report third quarter 2016 financial results and provide corporate update Source text for Eikon: Further company coverage:

Oct 27 2016

BRIEF-Otonomy reiterates financial guidance, says non-gaap operating expenses for 2017 would not exceed 2016

* Otonomy holds investor and analyst day and provides corporate update

Oct 07 2016

BRIEF-Otonomy successfully completes phase 2 clinical trial of otiprio in pediatric patients with acute otitis media with tympanostomy tubes

* Otonomy successfully completes phase 2 clinical trial of otiprio in pediatric patients with acute otitis media with tympanostomy tubes

Oct 04 2016

More From Around the Web

Earnings vs. Estimates